POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Sputnik Light vaccine has high safety and 93.5% efficacy against COVID

Christian Fernsby |
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the data from Paraguay’s Ministry of Health on the one shot Russian Sputnik Light vaccine (the first component of the Sputnik V vaccine) demonstrating high safety profile and a 93.5% efficacy, as reported during the ongoing vaccination campaign in the country.

Article continues below




The one shot Sputnik Light vaccine has proven to be highly effective against COVID among more than 320,000 subjects who had received the vaccine based on the data collected by July 30, 2021. The data also indicates a high safety profile of Sputnik Light:

No serious adverse events associated with vaccination;

No deaths related to the vaccination;

No cerebral vein thrombosis (CVT) cases after vaccination;

No Guillain-Barre syndrome (GBS) cases after vaccination;

No capillary leak syndrome cases after vaccination;

No cases of myocarditis or pericarditis reported.

Thanks to its safety and efficacy, single-component Sputnik Light vaccine is now both used on standalone basis and also studied in combination with vaccines from other producers in a number of countries.

The heterogeneous boosting approach (“vaccine cocktail” using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component) was at the core of Sputnik V, the world’s first registered vaccine against coronavirus. With this approach proving successful in creating a longer and more durable immunity against the coronavirus, RDIF took the lead in initiating partnerships with other vaccine producers to conduct joint studies of a combination of the first component of Sputnik V with foreign vaccines.

In particular, initial safety results of the world’s first study of a combination between Sputnik Light and the AstraZeneca vaccine in Azerbaijan demonstrates a high safety profile for the combined use of the vaccines with no serious adverse events or cases of coronavirus after vaccination.

Also RDIF, Ministry of Health of Argentina, Ministry of Science of Argentina and CONICET are conducting a study for the evaluation of the immune response and safety of heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm and Moderna in the city and province of Buenos Aires, as well as San Luis, Cordoba and La Rioja provinces. The results of the study will be published in a peer-reviewed medical journal.


What to read next

Hungary first in EU to approve Russian COVID-19 vaccine
WHO approves Sinopharm COVID-19 vaccine for emergency use
Russia approves trials of combined AstraZeneca/Sputnik V vaccine